Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations.


PURPOSE Medulloblastoma is the prototype of treatment success in modern pediatric neuro-oncology. Unfortunately, 20% to 30% of tumors recur despite maximal resection and multimodal therapy. Multiple biologic prognostic markers have been investigated to predict recurrences, but controversy remains regarding their clinical utility. Because p53… (More)
DOI: 10.1200/JCO.2009.23.5952